Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Mont...(same period in 2006. -- Sales o...),Health

2006.

-- Sales of ERBITUX(R), which is sold by the company almost exclusively in

the U.S., increased 11% to $185 million in the fourth quarter of 2007

from $167 million in the same period in 2006, due to growth in the use

for head and neck and colorectal cancer. ERBITUX(R) is marketed by the

company under a distribution and copromotion agreement with ImClone

Systems Incorporated.

-- Sales for SPRYCEL(TM), an oral inhibitor of multiple tyrosine kinases,

increased to $56 million in the fourth quarter of 2007 from $14 million

in the same period in 2006. This was due to launches in international

markets beginning in the fourth quarter of 2006 and the continued

growth in the U.S.

-- Sales of IXEMPRA(TM), a microtubule inhibitor for the treatment of

patients with metastatic or locally advanced breast cancer, were $15

million in the fourth quarter of 2007. IXEMPRA(TM) was launched in the

U.S. in October 2007.

HEALTH CARE GROUP

The combined fourth quarter 2007 revenues for the Health Care Group increased 9%, including a 5% favorable foreign exchange impact, to $1.0 billion compared to the same period in 2006. On January 8, 2008, the company completed the sale of Medical Imaging, which is presented as a discontinued operation.

Nutritionals

-- Worldwide Nutritional sales increased 8%, including a 4% favorable

foreign exchange impact, to $670 million in the fourth quarter of 2007

from $618 million in the same period in 2006. U.S. Nutritional sales

decreased 7% to $275 million in the fourth quarter of 2007, primarily

due to contract transitions under the Women, Infants and Children (WIC)

program. International Nutritional sales increased 22% to $395 million

in the fourth quarter of 2007, including a 9% favorable foreign

exchange i
'/>"/>